Clinical trial NCT02568748: Evaluation of Cytokine-induced Killer (CIK) Cells as Therapy or Adjuvant Treatment for Advanced HCC
Official title: Evaluation of Cytokine-induced Killer (CIK) Cells as Therapy or Adjuvant Treatment for Patients With Advanced Hepatocelluler Carcinoma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Liver Cancer
Lead sponsor: Tanta University
Sponsor class: OTHER
Collaborators: name: Tanta University
First posted: 2015-10-06
Enrollment: 20
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Hepatocellular carcinoma (HCC) is the fifth most common malignancy in the world and the third most common cause of cancer-related deaths complicating liver cirrhosis in most cases. In Egypt, there has been a remarkable increase of the proportion of HCC among CLD patients from 4.0% to 7.2% over a decade. This rising proportion may be explained by the increasing risk factors such as the emergence of HCV over the same period of time, the contribution of HBV infection, improvement of the screening programs and diagnostic tools of HCC as well as the increased survival rate among patients with cirrhosis to allow time for some of them to develop HCC. The only curative treatment modalities for HCC are surgery, local ablation, and liver transplantation which have high recurrence rate either due to viral hepatitis infection or cirrhosis leading to low success rate and high economic burden.

Unfortunately, the majority of patients have unresectable disease at diagnosis. So, patients search for palliative very expensive therapies including chemotherapy and radiotherapy which often fail to eradicate tumor lesions completely and tend to result in many adverse events.Thus, novel approaches for treatment options are needed for patients with advanced HCC .

In recent years, immunotherapy has emerged as an efficacious treatment modality with encouraging efficacy and slight adverse events in cancer therapy \[Stroncek 2010\]. Cytokine-induced killer CIK cells therapy has been evaluated as an adoptive cell immunotherapy for cancer patients in a number of clinical trials and the promising efficacy of CIK cells on malignancies has been proved.

Detailed description: Hepatocellular carcinoma (HCC) is the fifth most common malignancy in the world and the third most common cause of cancer-related deaths complicating liver cirrhosis in most cases. In Egypt, there has been a remarkable increase of the proportion of HCC among CLD patients from 4.0% to 7.2% over a decade. This rising proportion may be explained by the increasing risk factors such as the emergence of HCV over the same period of time, the contribution of HBV infection, improvement of the screening programs and diagnostic tools of HCC as well as the increased survival rate among patients with cirrhosis to allow time for some of them to develop HCC. The only curative treatment modalities for HCC are surgery, local ablation, and liver transplantation which have high recurrence rate either due to viral hepatitis infection or cirrhosis leading to low success rate and high economic burden..

Unfortunately, the majority of patients have unresectable disease at diagnosis. So, patients search for palliative very expensive therapies including chemotherapy and radiotherapy which often fail to eradicate tumor lesions completely and tend to result in many adverse events.Thus, novel approaches for treatment options are needed for patients with advanced HCC .

In recent years, immunotherapy has emerged as an efficacious treatment modality with encouraging efficacy and slight adverse events in cancer therapy. Cytokine-induced killer CIK cells therapy has been evaluated as an adoptive cell immunotherapy for cancer patients in a number of clinical trials and the promising efficacy of CIK cells on malignancies has been proved. . Clinical studies have demonstrated that it is an excellent method to prevent tumor recurrence and has preliminarily shown its efficacy in inhibiting recurrence and metastasis of primary HCC -Peripheral blood mononuclear cells (PBMC)from patients with primary HCC were incubated in vitro and induced into CIK cells in the presence of various cytokines such as interferon-gamma (IFN-ã ), interleukin-1 (IL-1), IL-2, and monoclonal antibody (mAb) against CD3. CIK cells infusion will be performed Once every week, with a total of at least4infusions. Infusion will be given intrahepatic or via peripheral veins .

The serial biological events following CIK cells administration to a cancer patient includes (a) immune activation and effective lymphocytes (mostly C D3+CD 5 6+Tlymphocytes) proliferation starting early after the first administration , ( b) clinically measurable antitumor effect mediated by activated immune cells over weeks to months ,and (c) potential delayed effect on patient survival several months or even longer after the first administration.

Our team have many grants in field of HCC biomarkers discovery and managements from NIH as multicenter studies which got many international publication. As well as grant for the use of laboratory techniques in the cultivation of stem cells for specialized cells used in the treatment of different diseases which got publication in this era. we aim in this project to cultivate patients cells in vitro to get CIK cells and study the safety and efficacy of immunization with specific antihepatocellular carcinoma Cytokine -induced killer cells in Egyptian patients with advanced hepatocellular carcinoma as treatment or adjuvant treatment in comparison with traditional treatment.

Eligibility criteria: Inclusion Criteria:

1. Patients with advanced HCC and not fit for resection or local ablative therapies stage B (according Barcelona Clinic Liver Cancer (BCLC) Staging system ).
2. Patient with HCC and portal vein thrombosis stage C.
3. Patients with HCC and lymphatic or distant metastases stage D.

Exclusion Criteria:

1. Patients with HCC and fit for radical or local ablation (stage 0 and A) therapies.
2. Platelet count below 50,000 / dl
3. Prothrombin activity below 50%
4. All patients will sign a written informed consent after explaining the details and possible hazards of the procedure to them. Those who will refuse to share in the study will be excluded.

Primary outcomes:
measure: Number of patients with ablated hcc
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Sherief Abd-Elsalam
state: Tanta
Study officials:
affiliation: Hepatology dept.-Tanta
name: Dina H Ziada, Prof
role: PRINCIPAL_INVESTIGATOR
affiliation: Hepatology dept.-Tanta
name: Hanan H Soliman, Prof
role: STUDY_DIRECTOR
affiliation: Clinical pathology dept.
name: Enas Arafa, Prof
role: STUDY_DIRECTOR
affiliation: Hepatology dept.-Tanta
name: Sherief Abd-Elsalam, lecturer
role: STUDY_DIRECTOR
affiliation: Pathology dept.- Cairo university
name: Abdelrahman Zekri, Professor
role: STUDY_CHAIR
affiliation: Interventional radiology- Tanta university
name: Amre Elbadry, Professor
role: STUDY_CHAIR
affiliation: Hepatology dept.- Tantauniversity
name: Marwa Salama, Ass.lecturer
role: STUDY_CHAIR
affiliation: Interventional radiology- Tanta university
name: Ahmed Elsharkawy, Ass.lecturer
role: STUDY_CHAIR
References: